[Tumor markers in the diagnosis of tumors in the subhepatic area].
Concentrations of CA 19-9, CA 50, CA 195 and DUPAN-2 were followed in serum, bile and pancreatic juice of 65 patients with malignant or benign lesions of CBD and/or pancrease. In sera, significant differences between neoplasias and benign lesions were seen only in patients with tumors in stages III. and IV. In the bile, however, the significant increase of DUPAN-2 and CA 195 were present in all stages of cholangiocarcinoma when compared with benign CBD lesions. In the pancreatic juice, the significant increase on of CA 19-9, CA 50 and DUPAN-2 in patients with pancreatic cancer (stages I-IV) could also be evidenced.